UK SACT Board
Good Practice Guidance for Immuno-Oncology Medications
The UK Systemic Anti-Cancer Treatment (SACT) board has updated in guidance on immuno-oncology medications in collaboration with the IOCN. This document is designed to give a practical framework for the safe introduction and ongoing use of immuno-oncology in existing SACT services.